News

The SADS Foundation just released a COVID-19 Vaccine statement that recommends that all individuals with SADS conditions receive a vaccination. Michael J. Ackerman, MD, PhD, director of the Long QT Syndrome Clinic and professor of medicine, pediatrics, and molecular pharmacology at the Mayo Clinic College of Medicine, Rochester, Minnesota and Chair, Board of Trustees, SADS Foundation said, "I've told all of my patients and every genetic heart patient we talk with at the SADS Foundation (Long QT syndrome, CPVT, Brugada syndrome, ARVC, etc.). If you are 16 years or older, you can get the vaccine, you should get the vaccine, it is safe for your heart."

Three new drugs have been added and one removed from the Possible Risk of TdP category for the QTdrugs list. Two drugs used for prostate cancer (Bicalutamide and Relugolix) and an antibiotic (Linezolid) have been added to the Possible Risk category. The drug combination product, Moexipril and Hydrocholorthiazide, was removed from the Possible Risk of TdP category due to labelling changes and a lack of supporting evidence of an effect on the QT interval.